LENVIMA is indicated for the first-line treatment of patients with unresectable hepatocellular carcinoma.
LENVIMA: Efficacy that drives results1
-
LENVIMA achieved its noninferiority primary endpoint vs sorafenib in OS; 13.6- vs 12.3-month median OS (HR: 0.92 [95% CI: 0.79-1.06]). LENVIMA did not demonstrate a statistically significant improvement in OS vs sorafenib1*
- Number of events: 351 (73%) with LENVIMA and 350 (74%) with sorafenib
Offering more time without disease progression1
-
7.3-month median PFS vs 3.6 months with sorafenib (HR: 0.64 [95% CI: 0.55-0.75]) P<0.001 (mRECIST)1
- Number of events: 311 (65%) with LENVIMA and 323 (68%) with sorafenib
OS=overall survival; HR=hazard ratio; CI=confidence interval; PFS=progression-free survival; mRECIST=modified Response Evaluation Criteria in Solid Tumors; AR=adverse reaction.
*Based on a stratified Cox-model. The noninferiority margin for the HR of LENVIMA vs sorafenib is 1.08.
Not an actual patient